Business
AI Stock Market Advice
CNBC’s Jim Cramer advised investors not to rush back into AI stocks. The market outlook for smaller companies is also pessimistic, according to Value Line analysis.
Coverage timeline — 3 articles
CNBC
CNBC’s Jim Cramer warned investors against rushing back into AI stocks quite yet.
2026-10-19 22:46 UTC
STAT News
The median net price for 202 newly launched medicines rose by 35%, to $257,000 last year from $173,000 in 2022.
2026-10-20 10:30 UTC
MarketWatch
The Value Line Median Appreciation Potential has a good record forecasting smaller stocks’ returns. And the next four years look bearish.
2026-10-20 10:30 UTC